- Home
- XOMAO vs LPLA Comparison
XOMAO vs LPLA Comparison
Compare XOMAO & LPLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAO
- LPLA
- Stock Information
- Founded
- XOMAO N/A
- LPLA 1989
- Country
- XOMAO United States
- LPLA United States
- Employees
- XOMAO 13
- LPLA N/A
- Industry
- XOMAO Biotechnology: Pharmaceutical Preparations
- LPLA Investment Bankers/Brokers/Service
- Sector
- XOMAO Health Care
- LPLA Finance
- Exchange
- XOMAO Nasdaq
- LPLA Nasdaq
- Market Cap
- XOMAO N/A
- LPLA N/A
- IPO Year
- XOMAO N/A
- LPLA 2010
- Fundamental
- Price
- XOMAO $25.26
- LPLA $383.39
- Analyst Decision
- XOMAO
- LPLA Strong Buy
- Analyst Count
- XOMAO 0
- LPLA 13
- Target Price
- XOMAO N/A
- LPLA $369.77
- AVG Volume (30 Days)
- XOMAO N/A
- LPLA 648.4K
- Earning Date
- XOMAO N/A
- LPLA 05-08-2025
- Dividend Yield
- XOMAO N/A
- LPLA 0.31%
- EPS Growth
- XOMAO N/A
- LPLA 9.05
- EPS
- XOMAO N/A
- LPLA 14.44
- Revenue
- XOMAO N/A
- LPLA $12,896,160,000.00
- Revenue This Year
- XOMAO N/A
- LPLA $25.62
- Revenue Next Year
- XOMAO N/A
- LPLA $11.57
- P/E Ratio
- XOMAO N/A
- LPLA $26.53
- Revenue Growth
- XOMAO N/A
- LPLA 25.70
- 52 Week Low
- XOMAO N/A
- LPLA $187.19
- 52 Week High
- XOMAO N/A
- LPLA $390.23
- Technical
- Relative Strength Index (RSI)
- XOMAO 53.03
- LPLA 65.19
- Support Level
- XOMAO $25.10
- LPLA $368.12
- Resistance Level
- XOMAO $25.30
- LPLA $387.92
- Average True Range (ATR)
- XOMAO 0.11
- LPLA 7.81
- MACD
- XOMAO 0.02
- LPLA -0.57
- Stochastic Oscillator
- XOMAO 73.81
- LPLA 69.06
About XOMAO AGNC Investment Corp.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.